Exact Sciences shared new modeling data that shows the impact of the Cologuard tests on patients, healthcare professionals and the U.S. healthcare system since its FDA approval a decade ago, the organization announced today.

According to a release, the Cologuard test has:

• Been used more than 16 million times,
• Detected 525,000 people with advanced precancerous lesions, and
• Contributed to 77% of the improvement in colorectal cancer (CRC) screening rates between 2018-2021.

“As Exact Sciences marks the 10th anniversary of Cologuard, we reflect on the vital role that it has played in the prevention and early detection of colorectal cancer, making screening more accessible and effective for patients,” Exact Sciences CEO and Chairman Kevin Conroy said in a statement. “We reached this milestone thanks to long-standing partnerships from health care professionals and advocacy organizations, as well as the support of our dedicated team.”

The Cologuard test has also saved the health system $22 billion due to pre-cancer and early cancer detection compared to no screening.